Related Experiment Videos
LEAPT: lectin-directed enzyme-activated prodrug therapy.
Mark A Robinson1, Stuart T Charlton, Philippe Garnier
1Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Mansfield Road, Oxford OX1 3TA, United Kingdom.
Summary
This study introduces a novel bipartite drug delivery system using engineered enzymes and prodrugs for targeted cancer therapy. This method enhances drug selectivity and efficacy, reducing toxicity in hepatocellular carcinoma models.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Delivery Systems
Background:
- Targeted drug delivery aims to reduce toxicity and enhance therapeutic efficiency.
- Exploiting endogenous molecular interactions is a key strategy for precise drug localization.
Purpose of the Study:
- To develop and evaluate a bipartite drug delivery system utilizing carbohydrate-lectin binding for targeted enzyme localization and subsequent prodrug activation.
- To engineer glycosylated enzyme conjugates for enhanced specificity and stability.
- To demonstrate therapeutic efficacy in a hepatocellular carcinoma model.
Main Methods:
- Enzyme engineering via deglycosylation and reglycosylation.
- In vivo and in vitro techniques including gamma scintigraphy, microautoradiography, and confocal microscopy for localization studies.
- Development and application of a doxorubicin prodrug (Rha-DOX) for cancer therapy.
Main Results:
- Demonstrated specific enzyme localization to hepatocytes via endocytosis, with a 60-fold increase in selectivity.
- Achieved a >30-fold increase in protein delivery to target cells.
- Engineered glycosylation enhanced enzyme stability and serum uptake.
- Successfully reduced tumor burden in a hepatocellular carcinoma model using the enzyme-activated prodrug therapy.
Conclusions:
- The developed bipartite system enables highly specific, enzyme-mediated prodrug activation at target sites.
- Glycosylation engineering is a powerful tool for improving enzyme characteristics for drug delivery.
- This lectin-directed enzyme-activated prodrug therapy shows significant therapeutic potential for targeted cancer treatment.